Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial
| Autor: | Akbar AliAsgarzadeh, Sanaz Karimiavval, Jalil Houshyar, Morteza Gojazadeh, Alireza Hadi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Journal of Clinical and Diagnostic Research, Vol 14, Iss 2, Pp OC01-OC04 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2249-782X 0973-709X |
| DOI: | 10.7860/JCDR/2020/43034.13481 |
| Popis: | Introduction: Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the beneficial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered as one or two days per week with higher compliance rates in patients. Aim: To determine the effect of Cabergoline on glycaemic control in patients with Type 2 Diabetes Mellitus (DM). Materials and Methods: In this double-blind clinical trial, initial laboratory parameters including Fasting Plasma Glucose (FBS), 2 Hours Postprandial Plasma Glucose (2HPPG), HbA1c, Total Cholesterol (T-Chol), Triglycerides (TG), and High Density Lipoproteins (HDL) were assessed. The subjects were randomly assigned into two case and control groups. The intervention group received 0.25 mg Cabergoline tablets weekly for the first 2 weeks and 0.5 mg per week for the next 12 weeks. Control group also received placebo tablets. All clinical and laboratory assessments were repeated 3 months after initial visit. Paired t-test, independent t-test and chi-square were used for the comparison of quantitative and qualitative variables, respectively. Covariance analysis was also used to adjust for confounding variables. p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|